search
Back to results

The Genetic Effects on Vitamin D Supplementation

Primary Purpose

Vitamin D Deficiency

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Vitamin D3 supplement
Sponsored by
St. Mary's University, Twickenham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Vitamin D Deficiency

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy adults female and male 18-65 years completion of physical activity readiness questionnaire (PAR-Q). Exclusion Criteria: Below 18 years above 65 years individuals taking medications that could interact with vitamin D status Individuals regularly taking daily Vitamin D supplementation during the 3 months before the intervention start date major dietary changes in vitamin D intake during the intervention period

Sites / Locations

  • St Mary's University TwickenhamRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Control (Low risk genotype)

Intervention (Medium risk genotype)

Intervention (High risk genotype)

Arm Description

Participants with no genetic variation in their VDR, GC and CYP2R1 genes that would increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group is a control against the medium and high-risk intervention groups.

Participants with genetic variation in their VDR, GC and CYP2R1 genes that moderately increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.

Participants with genetic variation in their VDR, GC and CYP2R1 genes that increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.

Outcomes

Primary Outcome Measures

vitamin D concentration
Effect between genetic variations and vitamin D concentration

Secondary Outcome Measures

Full Information

First Posted
September 14, 2022
Last Updated
March 24, 2023
Sponsor
St. Mary's University, Twickenham
search

1. Study Identification

Unique Protocol Identification Number
NCT05802433
Brief Title
The Genetic Effects on Vitamin D Supplementation
Official Title
Effects of VDR rs7311856, GC rs2282679 and CYP2R1 rs2060793 Variants on Vitamin D Status: A Randomised Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 16, 2022 (Actual)
Primary Completion Date
August 25, 2023 (Anticipated)
Study Completion Date
October 5, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Mary's University, Twickenham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Vitamin D is essential for skeletal growth and bone health, deficiency causes rickets and osteomalacia. In the UK 29% of adults have vitamin D deficiency. It is recommended all adults take 10µg vitamin D supplement daily. Genetic variations could alter vitamin D status by affecting vitamin D metabolism. Systematic reviews found variations in VDR, GC and CYP2R1 genes are associated with vitamin D deficiency. This study aims to assess the effects between vitamin D supplementation and variations in VDR, GC and CYP2R1 genes on vitamin D status.
Detailed Description
The study design is a quantitative, randomised control trial measuring vitamin D concentrations in blood serum. All participants will be given the recommended 10µg daily dose of vitamin D supplementation. Participants will be grouped based on their genotype for each gene, as either low, medium or high-risk genotypes. The low-risk group will act as a control and the medium and high-risk groups will act as the intervention groups. Participants will attend St Mary's University's applied science laboratory twice. During their first visit participants will provide a 2ml capillary blood sample. Blood samples are collected using lancets to prick participants' ear lobes. The serum is extracted from the blood samples, serum is stored at -80c until analysis. Participants will be given 90 10µg vitamin D supplements and instructed to take one per day for 90 days. Participants will also be instructed to not make any major changes to their habitual diet. During the second visit participants will provide 1 ml of saliva sample into the Collection Pot and a second 2ml sample of blood. Serum samples will be analysed for vitamin D concentrations using 25(OH) Vitamin D ELISA kit. DNA will be extracted from the saliva samples using PSP SalivaGene DNA Kit following the manufacturer's protocol. DNA will be genotyped for variations in the VDR, GC and CYP2R1 genes. Data will be assessed to determine if variations in these genes influenced the effectiveness of vitamin D supplementation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are grouped based on their genetic risk of vitamin D deficiency, all participants are given 10µg vitamin D supplements for 90 days
Masking
Participant
Masking Description
Participants are not informed of their genetic variations until completion of the trial
Allocation
Randomized
Enrollment
67 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control (Low risk genotype)
Arm Type
Experimental
Arm Description
Participants with no genetic variation in their VDR, GC and CYP2R1 genes that would increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group is a control against the medium and high-risk intervention groups.
Arm Title
Intervention (Medium risk genotype)
Arm Type
Experimental
Arm Description
Participants with genetic variation in their VDR, GC and CYP2R1 genes that moderately increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
Arm Title
Intervention (High risk genotype)
Arm Type
Experimental
Arm Description
Participants with genetic variation in their VDR, GC and CYP2R1 genes that increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3 supplement
Intervention Description
10µg vitamin D3 supplement per day for 90 days
Primary Outcome Measure Information:
Title
vitamin D concentration
Description
Effect between genetic variations and vitamin D concentration
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adults female and male 18-65 years completion of physical activity readiness questionnaire (PAR-Q). Exclusion Criteria: Below 18 years above 65 years individuals taking medications that could interact with vitamin D status Individuals regularly taking daily Vitamin D supplementation during the 3 months before the intervention start date major dietary changes in vitamin D intake during the intervention period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yiannis Mavrommatis
Phone
020 8240 4000
Email
yiannis.mavrommatis@stmarys.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yiannis Mavrommatis
Organizational Affiliation
St. Mary's University, Twickenham
Official's Role
Principal Investigator
Facility Information:
Facility Name
St Mary's University Twickenham
City
London
State/Province
Lobdon
ZIP/Postal Code
TW1 4SX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yiannis Mavrommatis
Phone
020 8240 4000
Email
yiannis.mavrommatis@stmarys.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34578986
Citation
Krasniqi E, Boshnjaku A, Wagner KH, Wessner B. Association between Polymorphisms in Vitamin D Pathway-Related Genes, Vitamin D Status, Muscle Mass and Function: A Systematic Review. Nutrients. 2021 Sep 4;13(9):3109. doi: 10.3390/nu13093109.
Results Reference
background
Citation
National Health Service (NHS) (2020) Vitamin D. Available at: https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/
Results Reference
background
Citation
National Institute for Health and Care Excellence (NICE) (2017) Vitamin D: supplement use in specific population groups. Available at: https://www.nice.org.uk/guidance/ph56/
Results Reference
background
Citation
Public Health England (PHE) (2019) National Diet and Nutrition Survey: Years 1 to 9 of the Rolling Programme (2008/2009 - 2016/2017): Time trend and income analyses. Available at: https://assets.publishing.service.gov.uk/
Results Reference
background
PubMed Identifier
31678109
Citation
Sepulveda-Villegas M, Elizondo-Montemayor L, Trevino V. Identification and analysis of 35 genes associated with vitamin D deficiency: A systematic review to identify genetic variants. J Steroid Biochem Mol Biol. 2020 Feb;196:105516. doi: 10.1016/j.jsbmb.2019.105516. Epub 2019 Oct 31.
Results Reference
background

Learn more about this trial

The Genetic Effects on Vitamin D Supplementation

We'll reach out to this number within 24 hrs